ST. LOUIS & LEXINGTON, Mass.--(BUSINESS WIRE)--Appistry, a leading provider of high-performance computing and analytics solutions for next-generation medicine, and N-of-One, the leading provider of molecular interpretation and therapeutic strategies for personalized medicine in cancer care, today announced a partnership to jointly provide genetic sequencing data analysis and molecular interpretation services. This partnership will bring together actionable components that will enable clinicians to use genomic sequencing to better understand the molecular profile of a patient’s tumor and select appropriate targeted therapeutic options.
Under the terms of the agreement, N-of-One and Appistry will jointly market and sell N-of-One’s interpretation services and content together with Appistry’s bioinformatics next-generation sequencing analysis solutions and services to enable a complete workflow that will yield therapeutic insights and options from raw sequencing data. Terms of the agreement were not disclosed.
“The challenges and capabilities needed to realize the promise of precision medicine are very complex, which has meant that genomics-based approaches are limited to those willing and able to make major investments in infrastructure and expertise,” said Kevin Haar, President and CEO of Appistry. “By working together with N-of-One, we will make these critical services available to any clinician, regardless of geography, institutional size or affiliation. N-of-One’s industry-leading molecular interpretation services coupled with Appistry's expertise in analyzing, managing, and orchestrating massive data sets and workflow processes will pave the way to genomic testing becoming part of routine clinical practice.”
Together, Appistry and N-of-One will target diagnostic labs, healthcare providers and other healthcare organizations that want to adopt a complete knowledge solution for precision medicine.
“We are committed to our mission of enabling precision medicine for researchers and physicians by providing outstanding molecular interpretation. Working with Appistry, a leader in transforming vast quantities of data into actionable intelligence, we are able together to meet the needs of health care organizations who are implementing and offering advanced molecular profiling services to their oncology patients,” said Chris Cournoyer, CEO of N-of-One. “Together, we bring a complete solution for high quality, high value analytics and molecular profiling to the point of care, enabling oncologists and treating clinicians to most efficiently and effectively gain state-of-the-art knowledge and insights into possible treatment therapies specific to each patient.”
A leading provider of high-performance computing and analytics for managing big data, Appistry empowers medical researchers, oncologists, and clinicians to capitalize on genomics medicine. Appistry is also the authorized provider Broad tools for next-generation sequencing analysis, making the tools easier to implement and use in for-profit settings. Learn more by visiting www.appistry.com or following us on Facebook, Twitter, and LinkedIn.
N-of-One, a leader in precision medicine for oncology, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinical insights and therapeutic options focused on the point of care. N-of-One’s team of experts has interpreted more than 6,000 tumors for oncologists and patients worldwide, through partnerships to provide clinical interpretation for leading diagnostic companies (such as Foundation Medicine and Clarient), through agreements with provider networks (such as Fox Chase Cancer Center in Philadelphia), directly to oncologists and through employee access benefit programs (such as Life Technologies). N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.